European Commission approves Exblifep (cefepime and enmetazobactam )to treat complicated urinary tract infections, pyelonephritis, hospital-acquired pneumonia ,and ventilator-associated pneumonia.- Advanz Pharma
Advanz Pharma Holdco Limited a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines in Europe, Canada, and Australia, and Allecra Therapeutics , a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced that the EC granted a marketing authorization for Exblifep an antibiotic fixed-dose combination of cefepime and enmetazobactam.
Exblifep is approved for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis; hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP); and bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed previously.
Advanz Pharma owns the rights to develop and commercialise Allecra’s antibiotic drug candidate, cefepime/enmetazobactam, within the European Union, the United Kingdom, Switzerland, and Norway.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins